L3VLUP
ProSign in

CERS · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

CERSVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • CERS
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterCERSVRTX
Q3 20201 holders, $188m31 holders, $21.9bn
Q4 20203 holders, $205m30 holders, $18.4bn
Q1 20213 holders, $154m31 holders, $15.4bn
Q2 20212 holders, $124m30 holders, $12.7bn
Q3 20212 holders, $104m35 holders, $10.1bn
Q4 20212 holders, $107m28 holders, $12.4bn
Q1 20223 holders, $90m23 holders, $16.1bn
Q2 20223 holders, $86m25 holders, $18.1bn
Q3 20223 holders, $61m22 holders, $18.4bn
Q4 20223 holders, $59m28 holders, $18.4bn
Q1 20232 holders, $66m26 holders, $21.4bn
Q2 20231 holders, $51m27 holders, $24.7bn
Q3 20231 holders, $33m33 holders, $24.3bn
Q4 20231 holders, $45m32 holders, $28.6bn
Q1 20241 holders, $41m31 holders, $29.8bn
Q2 20241 holders, $35m29 holders, $33.4bn
Q3 20241 holders, $32m27 holders, $33.5bn
Q4 20241 holders, $32m26 holders, $28.5bn
Q1 20251 holders, $29m21 holders, $35.4bn
Q2 20251 holders, $27m21 holders, $32.3bn
Q3 20251 holders, $30m22 holders, $25.9bn
Q4 20251 holders, $37m26 holders, $31.8bn
Q1 20261 holders, $35m25 holders, $31.8bn
Q2 20261 holders, $52m26 holders, $34.6bn
CERS

Cerus Corp

Holders
1
Reported value
$32m
Buyers
0
Sellers
1

Breadth -1 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
27
Reported value
$33.5bn
Buyers
17
Sellers
10

Breadth +7 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q3 2024

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only CERS (0)

None.

Only VRTX (26)

AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Baillie Gifford & Co, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Egerton Capital UK LLP, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Neuberger Berman Group LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, and 1 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →